Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arcutis Biotherapeutics Inc
ARQTCurrent price
9.26 USD
-0.58 USD (-5.89%)
Last closed
9.93 USD
Company
www.arcutis.com
ISIN
US03969K1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 266 426 880 USD
Yield for 12 month
+374.87 %
1Y
3Y
5Y
10Y
15Y
ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19 USDP/E ratio
–Dividend Yield
–Current Year
+59 606 000 USD
Last Year
+3 686 000 USD
Current Quarter
+44 755 000 USD
Last Quarter
+30 858 000 USD
Current Year
+53 488 000 USD
Last Year
+2 932 000 USD
Current Quarter
+39 252 000 USD
Last Quarter
+27 394 000 USD
Key Figures ARQT
1 year
3 years
5 years
10 years
EBITDA
-179 408 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-31.14 %
PEG Ratio
–
Return On Equity TTM
-192.31 %
Wall Street Target Price
19 USD
Revenue TTM
138 708 000 USD
Book Value
1.34 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
17.4 %
Dividend Yield
–
Gross Profit TTM
2 932 000 USD
Earnings per share
-1.67 USD
Diluted Eps TTM
-1.67 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-140.97 %
Dividend Analytics ARQT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ARQT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ARQT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8.2478
Price Sales TTM
9.1302
Enterprise Value EBITDA
-2.0404
Price Book MRQ
8.0849
Financials ARQT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ARQT
For 52 weeks
1.76 USD
13.17 USD
50 Day MA
9.67 USD
Shares Short Prior Month
27 129 867
200 Day MA
9.31 USD
Short Ratio
14.47
Shares Short
28 064 868
Short Percent
29.71 %
BeatStart